All In Biotech

Free tool

FAERS Monitor: Cerdelga

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 205494 or its brand name (Cerdelga, Eliglustat Tartrate). Reports on generic versions are filed under their own applications.

Reports

1,659

Serious

480

29% of reports

Hospitalization

215

Death reported

21

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • weight increased175
  • product dose omission in error162
  • weight decreased150
  • fatigue79
  • product dose omission issue76
  • dyspepsia54
  • arthralgia53
  • fall53
  • nausea51
  • dizziness45
  • off label use43
  • covid-1942
  • diarrhoea41
  • nasopharyngitis41
  • headache39

Reports by year received

View as table
YearReports
20147
201595
201647
201738
201868
2019129
202078
2021153
2022251
2023192
2024178
2025223
2026200

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,500 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
product dose omission in errorSignal16272.963.011,373
weight increasedSignal1759.98.61,408
dyspepsiaSignal547.05.4271
weight decreasedSignal1506.85.9748
product dose omission issueSignal763.32.6120
covid-19Signal423.02.356
nasopharyngitisSignal412.82.147
fallSignal532.01.527
arthralgia531.61.212
fatigue791.31.05
dizziness451.10.91
nausea510.80.62
diarrhoea410.80.62
headache390.80.62
off label use430.60.510

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.